BNTC
HEALTHCAREBenitec Biopharma Inc
$12.57+0.37 (+3.03%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving BNTC Today?
No stock-specific AI insight has been generated for BNTC yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$9.85$17.15
$12.57
Fundamentals
Market Cap$431M
P/E Ratio—
EPS$-1.08
Dividend Yield—
Dividend / Share—
ROE-0.3%
Profit Margin—
Debt / Equity—
Trading
Volume116K
Avg Volume (10D)—
Shares Outstanding34.3M
BNTC News
20 articles- Benitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the 2026 American Society of Gene and Cell Therapy Annual MeetingYahoo Finance·Apr 28, 2026
- Benitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued Progress for BB-301, the Only Clinical-Stage Therapeutic in Development for Oculopharyngeal Muscular Dystrophy (OPMD)Yahoo Finance·Mar 10, 2026
- Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Treatment at the 2026 Muscular Dystrophy Association Clinical & Scientific ConferenceYahoo Finance·Mar 9, 2026
- Benitec Biopharma Announces Acceptance of Late- Breaking Abstract for the BB-301 Phase 1b/2a Clinical Treatment Study at the Muscular Dystrophy Association Clinical & Scientific ConferenceYahoo Finance·Feb 23, 2026
- Here's Why We're Not At All Concerned With Benitec Biopharma's (NASDAQ:BNTC) Cash Burn SituationYahoo Finance·Feb 14, 2026
- Benitec Biopharma Releases Second Quarter 2026 Financial Results and Provides Operational UpdateYahoo Finance·Feb 12, 2026
- Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of ResponseYahoo Finance·Jan 11, 2026
- Does Benitec Biopharma (BNTC) Have the Potential to Rally 83.87% as Wall Street Analysts Expect?Yahoo Finance·Dec 24, 2025
- Wall Street Analysts Predict an 87.48% Upside in Benitec Biopharma (BNTC): Here's What You Should KnowYahoo Finance·Dec 5, 2025
- Down 25.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Benitec Biopharma (BNTC)Yahoo Finance·Dec 3, 2025
- Citizens Lifts Benitec Biopharma Inc. (BNTC) Price Target on Topline Results for Oculopharyngeal Muscular Dystrophy TreatmentYahoo Finance·Nov 18, 2025
- Hedge funds investors have a lot riding on Benitec Biopharma Inc. (NASDAQ:BNTC) with 37% ownershipYahoo Finance·Nov 18, 2025
- Benitec Biopharma Releases First Quarter 2026 Financial Results and Provides Operational UpdateYahoo Finance·Nov 14, 2025
- Big Insider Purchases by Carl Icahn, Mario Gabelli, and Others247 Wall St·Nov 12, 2025
- Benitec Biopharma Inc. Announces Pricing of $100 Million Common Stock OfferingYahoo Finance·Nov 6, 2025
- Benitec Biopharma Inc. Announces Proposed Public OfferingYahoo Finance·Nov 5, 2025
- Benitec Biopharma Provides Positive Interim Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial and Receives FDA Fast Track Designation for BB-301Yahoo Finance·Nov 3, 2025
- Benitec Biopharma Announces Appointment of Sharon Mates Ph.D. to its Board of DirectorsYahoo Finance·Nov 3, 2025
- Benitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular DystrophyYahoo Finance·Nov 3, 2025
- Benitec Biopharma Releases Full Year 2025 Financial Results and Provides Operational UpdateYahoo Finance·Sep 22, 2025
All 20 articles loaded
Price Data
Open$0.00
Previous Close$12.20
Day High$0.00
Day Low$0.00
52 Week High$17.15
52 Week Low$9.85
52-Week Range
$9.85$17.15
$12.57
Fundamentals
Market Cap$431M
P/E Ratio—
EPS$-1.08
Dividend Yield—
Dividend / Share—
ROE-0.3%
Profit Margin—
Debt / Equity—
Trading
Volume116K
Avg Volume (10D)—
Shares Outstanding34.3M
About Benitec Biopharma Inc
Benitec Biopharma Inc., a developing biotechnology company, is focused on the development of new genetic drugs. The company is headquartered in Hayward, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—